BackgroundThe tumor microenvironment plays a crucial role in the oncogenesis and treatment of diffuse large B-cell lymphoma (DLBCL). The H3K9me3-specific histone methyltransferase Suppressor of variegation 3-9 homolog 1 (SUV39H1) is a significant gene that promotes the progression of various malignancies. However, the specific expression of SUV39H1 in DLBCL remains unclear.MethodsBy retrieving data from GEPIA, UCSC XENA and TCGA public databases, we observed the high expression of SUV39H1 in DLBCL. Combined with an immunohistochemical validation assay, we analyzed our hospital's clinical characteristics and prognosis of 67 DLBCL patients. The results showed that high SUV39H1 expression was closely associated with age over 50 years (P = 0.014) and low albumin levels (P = 0.023) of patients. Furthermore, the experiments in vitro were deployed to evaluate the regulation of SUV39H1 on the DLBCL immune microenvironment.ResultsThe results showed that high SUV39H1 expression was closely associated with age over50 years (P = 0.014) and low albumin levels (P = 0.023) of patients. The prognostic analysis showed that the high SUV39H1 expression group had a lower disease-free survival (DFS) rate than the low SUV39H1 expression group (P < 0.05). We further discovered that SUV39H1 upregulated the expression of CD86(+) and CD163(+) tumor-associated macrophages by DLBCL patients' tissues and cell experiments in vitro (P < 0.05). And SUV39H1-associated T lymphocyte subsets and cytokines IL-6/CCL-2 were downregulated in DLBCL (P < 0.05).ConclusionsIn summary, SUV39H1 might be not only a potential target for treating DLBCL but also a clinical indicator for doctors to evaluate the trend of disease development.

Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) has been regarded as the standard treatment regimen for classical Hodgkin lymphoma. In recent years, ABVD-like regimens, which emerged due to shortages and the lung toxicity of bleomycin or the emergence of immune checkpoint inhibitors and antibody–drug conjugates, may be favorable, but have not yet been tested. We compared the outcomes of ABVD with ABVD-like regimens, which include bleomycin was completely or partially omitted; meanwhile, etoposide or PD-1 inhibitors were added. 5-Year progression-free survival (PFS) was higher for ABVD than ABVD-like regimens in young patients (82.1

ObjectiveThe prognostic nutritional index (PNI) is an important prognostic factor for survival outcomes in various hematological malignancies. The current study focused on exploring the predictive value of the PNI in newly diagnosed follicular lymphoma (FL) in China.Materials and methodsThe clinical indicators and follow-up data of 176 patients who received chemotherapy or immunotherapy combined with chemotherapy with FL in our hospital from January 2016 to March 2022 were retrospectively analyzed. Cox proportional hazard model was used for univariate and multivariate analyses. Kaplan–Meier curves were used to calculate survival rates and draw survival curves. The log-rank test was applied to compare differences between groups.ResultsThe optimal cut-off value of PNI was 44.3. All patients were divided into a high PNI group (>44.3) and a low PNI group (≤44.3). The low PNI group had a low CR rate and a high risk of death, with a tendency toward POD24, and Both OS and PFS were worse than those in the high PNI group. PNI was able to predict OS and PFS in FL patients and was the only independent predictor of OS (P = 0.014 HR 5.024; 95%CI 1.388∼18.178) in multivariate analysis. PNI could re-stratify patients into groups of high FLIPI score, high FLIPI2 score, no POD24, and rituximab combined with chemotherapy. Moreover, integrating PNI into the FLIPI and FLIPI2 models improved the area under the curve (AUC) for more accurate survival prediction and prognosis.ConclusionPNI is a significant prognostic indicator for newly diagnosed FL in China that can early identify patients with poor prognosis and guide clinical treatment decisions.

目的:探索含西达本胺(chidamide)方案治疗复发难治性非特指型外周T细胞淋巴瘤(peripheral T-cell lymphoma,not otherwise specifed,PTCL-NOS)的疗效与安全性.方法:回顾性分析 2017 年 12 月 1 日—2021 年 9 月 20 日在郑州大学第一附属医院接受含西达本胺方案治疗的 21 例复发难治性PTCL-NOS患者的疗效、预后和不良反应.其中,7 例接受西达本胺联合PD-1 抑制剂+吉西他滨+来那度胺方案治疗(西达本胺联合PD-1 抑制剂组),7 例接受西达本胺联合泼尼松+依托泊苷+沙利度胺(prednisone+etoposide+thalidomide,PET)方案治疗(西达本胺联合PET方案组),7 例接受西达本胺联合沙利度胺或来那度胺+泼尼松(thalidomide/lenalidomide+prednisone,TP/LP)方案治疗(西达本胺联合TP/LP方案组).观察 3 组的近期疗效、不良反应和生存结果.结果:21 例复发难治性PTCL-NOS患者中,完全缓解 3 例,部分缓解 7 例,客观缓解率为 47.6％.西达本胺联合PD-1 抑制剂方案组、西达本胺联合PET方案组以及西达本胺联合TP/LP方案组的客观缓解率分别为 71.4％、28.6％和 42.9％,3 组之间的差异无统计学意义(P= 0.090).21 例患者的1 年总生存率和无进展生存率分别为 95.8％和 83.8％,2 年总生存率和无进展生存率分别为 71.8％和 71.3％.3 组的总生存和无进展生存曲线的差异均无统计学意义(P= 0.367,P= 0.082).主要的不良反应为骨髓抑制和胃肠反应,大多可以通过对症治疗和调整药物剂量予以缓解.结论:含西达本胺方案可以作为复发难治性PTCL-NOS患者安全而有效的治疗选择.西达本胺联合PD-1 抑制剂方案可能显示出潜在的临床效应,但其对预后的影响仍需更多临床数据的支持.

Secondary Hemophagocytic Syndrome (HPS), also known as Hemophagocytic Lymphohistocytosis (HLH), is a life-threatening syndrome caused by secondary overstimulation of the immune system, with a high mortality rate even after appropriate treatment. HLH is often triggered by malignancies, infections or autoimmune diseases with the Malignancy-Associated Hemophagocytic Syndrome (MAHS) accounting for the highest proportion of secondary HLH (about 48%), and Lymphoma Associated Hemophagocytic Syndrome (LAHS) being the most common [1–3]. Among the LAHS cases, T/NK-cell lymphoma is much more common than the rarely seen B-cell lymphoma [4]. B-cell LAHS (B-LAHS) is predominantly described in Asian populations but larger sets are rare. Early clinical manifestations of HLH are nonspecific, mostly manifesting in persistent fever, pancytopenia and hepatosplenomegaly with an aggressive disease progress [5]. Therefore, early diagnosis and immediate introduction of appropriate treatment are crucial for these patients.

Background: Epigenetic regulation plays vital roles in the oncogenesis and treatment of diffuse large B-cell lymphoma (DLBCL). The H3K9me3-specific histone methyltransferase SUV39H1 is an epigenetic gene that promotes the progression of a variety of malignancies. However, the roles of SUV39H1 in DLBCL remain unclear. Methods: Initially, the Oncomine, Cancer Cell Line Encyclopedia (CCLE), UALCAN and Gene Expression Profiling Interactive Analysis (GEPIA) databases were searched to explore the expression of SUV39H1 in DLBCL. The clinical parameters and pathological sections of 61 successive patients, including 47 cases of DLBCL and 14 cases of reactive lymphoid hyperplasia, were collected from January 2019 to November 2020. Immunohistochemistry was conducted to verify the results of the database search. Finally, relevant parameters and pathological results were combined to analyze the expression of SUV39H1. Results: We found that the expression of SUV39H1 in DLBCL tissues was higher than that in normal and other cancer tissues (P<0.05) in database and immunohistochemistry analyses. Among the analyzed clinical parameters, only tumor size was closely associated with SUV39H1 ( P =0.037), suggesting that patients with high SUV39H1 expression are less likely to develop tumors over 7.5 cm in size. Regarding survival, the group with high SUV39H1 expression had a lower survival rate than the group with low SUV39H1 expression in terms of 10-year disease-free survival (DFS) according to the database analyses ( P =0.035). However, SUV39H1 was revealed as an independent predictor of overall survival (OS) and progression-free survival (PFS) in patients from both databases and our hospital ( P >0.05). Conclusion: SUV39H1 expression is higher in DLBCL tissues than in normal and other cancer tissues, indicating that DLBCL patients may not develop bulky tumors over follow-up and suggesting that SUV39H1 might serve not only as a predictive factor in the clinic but also as a target for the epigenetic therapy of DLBCL.

目的:观察来那度胺单药及联合利妥昔单抗维持治疗滤泡性淋巴瘤(follicular lymphoma,FL)的疗效及安全性.方法:24例FL患者接受R-CHOP方案足程化疗后获得完全缓解(complete response,CR),于2018年1月-2021年1月继续接受维持治疗.按维持治疗方案,分为仅接受来那度胺单药维持治疗(6例)、来那度胺联合利妥昔单抗维持治疗(6例)、利妥昔单抗维持治疗(6例)以及未接受维持治疗(6例).观察不同的维持治疗方案组FL患者的疗效、生存情况和不良反应.结果:中位随访时间为20.5个月(范围:6～37个月).来那度胺单药组、来那度胺联合利妥昔单抗组、利妥昔单抗组和未接受维持治疗组的客观缓解率分别为83.3％、50.0％、50.0％和33.3％,差异无统计学意义(P=0.458);中位PFS期分别为6.0、8.5、19.0和15.0个月,1年无进展生存率分别为100.0％、62.5％、100.0％和83.3％,总生存和无进展生存曲线的组间差异均无统计学意义(P=0.256,P=0.268).血液学不良反应以骨髓抑制为主.3个维持治疗组不良反应的差异无统计学意义(P＞0.05).结论:来那度胺单药及联合利妥昔单抗对FL进行维持治疗未能得到明显的生存获益,有待进一步探索和分析.